The Skin Cancer Education and Research Foundation – Home › Forums › Targeted therapy › Other › Adjuvant Treatment with Targeted Therapy › Reply To: Adjuvant Treatment with Targeted Therapy
We really haven’t used it in the adjuvant setting as of yet. We are treating patients mainly either in a adjuvant clinical trial or with Nivolumab. What I found intersting in the adjuvant BRAF study is was there was a higher incidence of pyrexia compared to the metastatic studies. The Pyrexia can really affect patients quality of life which makes it difficult to justify in the adjuvant setting.